180 related articles for article (PubMed ID: 8491331)
21. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
22. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women.
Massai R; Miranda P; Valdés P; Lavín P; Zepeda A; Casado ME; Silva MA; Fetis G; Bravo C; Chandía O; Peralta O; Croxatto HB; Díaz S
Contraception; 1999 Jul; 60(1):9-14. PubMed ID: 10549447
[TBL] [Abstract][Full Text] [Related]
23. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
24. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
Prescrire Int; 2006 Apr; 15(82):50-3. PubMed ID: 16604729
[TBL] [Abstract][Full Text] [Related]
25. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.
Mostad SB; Overbaugh J; DeVange DM; Welch MJ; Chohan B; Mandaliya K; Nyange P; Martin HL; Ndinya-Achola J; Bwayo JJ; Kreiss JK
Lancet; 1997 Sep; 350(9082):922-7. PubMed ID: 9314871
[TBL] [Abstract][Full Text] [Related]
26. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
[TBL] [Abstract][Full Text] [Related]
27. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change?
Barton SE; Maddox PH; Jenkins D; Edwards R; Cuzick J; Singer A
Lancet; 1988 Sep; 2(8612):652-4. PubMed ID: 2901519
[TBL] [Abstract][Full Text] [Related]
28. Initial UK experience of the levonorgestrel-releasing contraceptive intravaginal ring.
Sahota J; Barnes PM; Mansfield E; Bradley JL; Kirkman RJ
Adv Contracept; 1999; 15(4):313-24. PubMed ID: 11145373
[TBL] [Abstract][Full Text] [Related]
29. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Kononova ES
Contraception; 1990 Feb; 41(2):105-24. PubMed ID: 2107054
[TBL] [Abstract][Full Text] [Related]
30. Cervical cytology associated with levonorgestrel contraception.
Misra JS; Engineer AD; Tandon P
Acta Cytol; 1995; 39(1):45-9. PubMed ID: 7847008
[TBL] [Abstract][Full Text] [Related]
31. Current status of research and development of vaginal contraceptive rings as a fertility control method in the female.
Roy S; Mishell Dr
Res Front Fertil Regul; 1983 May; 2(4):1-10. PubMed ID: 12227323
[TBL] [Abstract][Full Text] [Related]
32. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant).
Clark DA; Wang S; Rogers P; Vince G; Affandi B
Hum Reprod; 1996 Jul; 11(7):1438-44. PubMed ID: 8671483
[TBL] [Abstract][Full Text] [Related]
33. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel.
Pakarinen PI; Lähteenmäki P; Lehtonen E; Reima I
Hum Reprod; 1998 Jul; 13(7):1846-53. PubMed ID: 9740437
[TBL] [Abstract][Full Text] [Related]
34. Dysplasia and cytologic findings in 4,589 young women enrolled in diethylstilbestrol-adenosis (DESAD) project.
Robboy SJ; Szyfelbein WM; Goellner JR; Kaufman RH; Taft PD; Richard RM; Gaffey TA; Prat J; Virata R; Hatab PA; McGorray SP; Noller KL; Townsend D; Labarthe D; Barnes AB
Am J Obstet Gynecol; 1981 Jul; 140(5):579-86. PubMed ID: 7195652
[TBL] [Abstract][Full Text] [Related]
35. Microflora of cervical and vaginal secretion in women using copper- and norgestrel-releasing IUCDs.
Ulstein M; Steier AJ; Hofstad T; Digranes A; Sandvei R
Acta Obstet Gynecol Scand; 1987; 66(4):321-2. PubMed ID: 3122515
[TBL] [Abstract][Full Text] [Related]
36. Lea's Shield, a new barrier contraceptive preliminary clinical evaluations three-day tolerance study.
Hunt WL; Gabbay L; Potts M
Contraception; 1994 Dec; 50(6):551-61. PubMed ID: 7705097
[TBL] [Abstract][Full Text] [Related]
37. [Menstrual blood loss and body iron stores: comparative study between a Multiload-375 IUD and a levonorgestrel vaginal ring].
Souza JP; Andrade AT; Pizarro E
Bol Cent Biol Reprod; 1991; 10(1):26-32. PubMed ID: 12318141
[TBL] [Abstract][Full Text] [Related]
38. Study of the abnormal cervical-vaginal cytology of sexually active young women living within the Waterloo region.
Redmond M; Schumacher B
Can J Public Health; 1990; 81(3):235-6. PubMed ID: 2361216
[TBL] [Abstract][Full Text] [Related]
39. Endometrial vasculature in Norplant users.
Rogers PA
Hum Reprod; 1996 Oct; 11 Suppl 2():45-50. PubMed ID: 8982745
[TBL] [Abstract][Full Text] [Related]
40. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women.
Landgren BM; Hall PE; Cekan SZ
Contraception; 1992 Apr; 45(4):343-9. PubMed ID: 1516366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
